Intellia Therapeutics, Inc. NTLA
11.75
(0.41)
(3.37%)
as of 25 Sep
- Market cap
- $1.7B
- P/E
- 0.0×
Follow NTLA
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(52.11%) | (53.48%) | (56.34%) | (55.44%) | |
| (42.49%) | (40.60%) | (45.23%) | (45.55%) | ||
ROIC |
(126.05%) | (124.43%) | (107.35%) | (91.28%) | |
Return on Tangible Assets |
(87.65%) | (93.48%) | (97.31%) | (86.29%) | |
Average Days of Receivables |
70.11 | 51.07 | 50.43 | 44.91 | |
Free Cash Flow per Share |
(3.74) | (3.65) | (3.07) | (2.61) | |
Free Cash Flow |
(412.63) | (395.86) | (363.62) | (348.60) | |
Capital Expenditures |
(1.98) | (1.13) | (0.47) | (1.95) | |
Piotroski F-Score |
3.00 | 3.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(32.60%) | (35.20%) | (36.43%) | (29.74%) | |
Accounts Receivable Turnover |
5.78 | 7.53 | 6.73 | 6.37 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
725.01% | 574.63% | 546.47% | 582.68% | |
Selling, General and Administrative Expense of Revenue |
207.15% | 177.03% | 190.09% | 228.98% | |
Share Based Compensation of Revenue |
179.21% | 118.54% | 108.72% | 114.10% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.92 | 0.96 | 0.92 | 0.87 | |
Depreciation/Fixed assets |
0.61 | 0.90 | 1.01 | 1.01 | |
Capex/Depreciation |
(0.16) | (0.07) | (0.03) | (0.13) | |
Revenue per Share |
0.52 | 0.62 | 0.56 | 0.45 | |
Operating CF per Share |
(3.73) | (3.64) | (3.06) | (2.60) | |
Capex per Share |
(0.02) | (0.01) | 0.00 | (0.01) | |
Capex to Sales |
0.03 | 0.02 | 0.01 | 0.03 | |
Net Profit Margin |
(774.94%) | (609.85%) | (597.04%) | (672.16%) |
Columns are period end dates